NMP22 Test Kit
The first ELISA for bladder cancer is the NMP22 test kit, manufactured by Matritech Inc, Newton, Mass, for Inverness Medical Professional Diagnostics, San Diego. The quantitative microplate test, which detects elevated levels of nuclear matrix protein in a urine sample, is considered useful for both screening and monitoring applications. Its use requires a physician’s prescription at present, although Inverness and Matritech are developing a home-use version, the NMP22 BladderChek, that will be available over the counter following FDA approval. This is expected to be the first at-home test for any type of cancer.

The NMP technology, developed at the Massachusetts Institute of Technology, is reported by Inverness to be twice as sensitive as urine cytology in detecting transitional-cell carcinoma of the urinary tract (responsible for nine of 10 bladder cancers). Occult disease and recurrent cancer are readily diagnosed in their early stages using this method.http://64.233.169.132/search?q=cache...

------------------------------------...
Article Date: 07 Jun 2008 - 0:00 PDT

There were 260 patients who had NMP22 determination. 197 were parenchymal tumors, 41 were UT-TCC, and 22 were inflammatory/infectious. NMP22 was positive in 11.7% of parenchymal, 78.5% of urothelial, and 4.5% of inflammatory lesions. Sensitivity of NMP22 in predicting presence of UT-TCC was 78.0%, specificity was 88.3%, positive predictive value was 59.2%, and negative predictive value was 95.0%. Multivariate analysis demonstrated age of 60 years (OR 2.46, p=0.047), TCC pathology (OR 37.0, p<0.001) and smoking history (OR 10.6, p=0.001) were significantly associated with NMP22 positivity.

http://64.233.169.132/search?q=cache...